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Background. The antibody response to pneumococcal conjugate vaccines (PCVs) in infants is variable. Factors
responsible for this variability have not been fully elucidated. The objective of this study was to investigate whether
pneumococcal carriage around the time of the first dose of 7-valent PCV (PCV7) affects serotype-specific im-
munologic response.
Methods. Healthy 2-month old infants were randomized to receive 2 (at the ages of 4 and 6 months) or 3
(at the ages of 2, 4, and 6 months) PCV7 doses and a booster dose (at the age of 12 months). Nasopharyngeal
or oropharyngeal specimens were obtained for culture shortly before the first PCV7 dose. Serotype-specific im-
munoglobulin (Ig) G levels were measured at ages 2, 7, and 13 months.
Results. Of 545 children studied, 332 received a booster dose. The most common serotypes carried around
the time of the first PCV7 dose were 6B (np37), 19F (np22), and 23F (np14). In carriers before the first
dose, the IgG response to the carried serotype after 2 or 3 doses was significantly lower than in noncarriers. In
contrast, response to the noncarried serotypes was not affected. Although all children responded to the booster
dose, the response to the originally carried serotype was generally lower.
Conclusions. Serotype-specific hyporesponsiveness to PCV7 after pneumococcal carriage in infants is dem-
onstrated for the first time. This phenomenon was common, lasted for at least several months, and was only
partially overcome by the 12-month booster.
Trial registration. isrctn.org identifier: ISRCTN28445844.
Global prevention of pneumococcal disease and death
through vaccination with pneumococcal conjugate vac-
cines (PCVs) is now possible. In many developing
countries, early nasopharyngeal acquisition of Strep-
tococcus pneumoniae is associated with both high car-
riage in young infants and a high rate of pneumococcal
disease [1]. This is the main reason why the World
Health Organization’s Strategic Advisory Group of Ex-
perts (SAGE) recommended that the introduction of
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pneumococcal vaccination into developing countries be
considered a high priority [2].
Despite multiple studies conducted during 130 years,
the efficacy and effectiveness of 23-valent pneumococ-
cal polysaccharide vaccine (PPSV) in children and
adults remain poorly defined and the subject of con-
troversy [3]. Furthermore, repeated doses of PPSV are
associated with hyporesponsiveness, when antibody lev-
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els after a second antigenic challenge are lower than after the
first, either in the same individual or in age-matched individuals
receiving PPSV at the same time [4], a phenomenon previously
described with Neisseria meningitidis polysaccharides, mainly
the group C polysaccharides [5–7].
Protein polysaccharide conjugate vaccines, unlike unconju-
gated polysaccharide vaccines, induce T cell–dependent re-
sponses, making them already highly immunogenic during early
infancy. In addition, after priming with conjugate vaccines,
subsequent doses with either conjugate or polysaccharide vac-
cines evoke a booster response, rather than hyporesponsiveness
[5]. Furthermore, conjugate vaccines can overcome hypore-
sponsiveness evoked by polysaccharide vaccines, although the
response may be lower than in those not previously primed or
those primed with PCVs. This was found in both adults and
children immunized with meningococcus C vaccines [6–8] or
pneumococcal vaccines [9–11].
A recent report suggested that invasive disease caused by a
given serotype in children !18 months old can result in hy-
poresponsiveness to the infecting serotype, but not the other
serotypes included in the PCV7, after subsequent adminis-
tration of the 7-valent PCV conjugated to CRM197 (PCV7)
[5]. The authors speculated that this phenomenon could re-
flect immune paralysis due to large pneumococcal polysac-
charide antigen loads during invasive pneumococcal disease
(IPD) and/or a potential genetic basis for nonresponse to in-
dividual serotypes.
Pneumococcal carriage is considerably more frequent than
IPD [12] and may be associated with absorption and circulation
of the carried polysaccharide, although probably with lower
loads than during IPD. An indirect evidence of the polysac-
charide absorption during carriage is the association of pneu-
mococcal C polysaccharide detection in urine with pneumo-
coccal carriage in healthy children [13–16]. Our objective was
therefore to determine whether nasopharyngeal carriage of S.
pneumoniae serotypes included in PCV7, at or immediately
before the first PCV7 dose, affects the response to the primary
immunization series and/or to the booster dose.
METHODS
Setting. In southern Israel (the Negev region), the Jewish and
Bedouin populations, differing in their socioeconomic condi-
tions and lifestyles, live side by side. However, both have access
to the same medical services. The Jewish population is mainly
urban, whereas the Bedouin population, formerly desert no-
mads, is in transition to a western lifestyle [17]. Contact be-
tween children of the 2 populations is rare. The Bedouin pop-
ulation lives in scattered clusters and Bedouin townships,
whereas the Jewish population lives mostly in cities, with the
rest living in Jewish townships and villages. Children of the 2
populations do not frequent the same daycare facilities or
schools and do not have a common social life.
The Bedouin population is characterized by overcrowding,
lower education level, larger family size, and lower income than
the Jewish populations [17]. In 2004, the crude birth rate was
55.3 versus 21.0 births per 1000 population in the Bedouin
versus Jewish populations [18], respectively; the mean family
size ( standard deviation) in the Bedouin population was
8.20.9 persons versus only 3.20.1 in the Jewish population
[19]. The average monthly family income was 2-fold higher in
the Jewish population [18]. Hospitalization rates for respiratory
and other infectious diseases were higher among Bedouins [20].
Pneumococcal nasopharyngeal carriage is usually higher among
Bedouin infants than among Jewish infants (data not shown),
and maternally derived pneumococcal anti-polysaccharide an-
tibodies are often higher in young Bedouin infants [21].
All children in the area are born in 1 hospital, where they
also receive all emergency and inpatient services. Vaccines are
given in public sector mother and child health centers for a
token annual family membership fee. All children in Israel are
entitled to medical insurance free of charge.
Participants. Healthy infants presenting to the mother and
child health centers in southern Israel for vaccination were
screened for eligibility. The study included male and female
subjects aged 2 months3 weeks, presenting for routine im-
munization, for whom the parents or legal guardians signed
informed consent. Exclusion criteria were as follows: prema-
ture birth at !35 weeks; acute disease at enrollment; axillary
temperature 138.0C; any congenital abnormality judged to
be clinically important or any inherited metabolic disorder,
thrombocytopenia, or coagulation disorder; use of immune-
modifying drugs for 14 days; known or suspected allergy or
intolerance to constituents of products administered in the
study; hypotonic-hyporesponsiveness or persistent inconsol-
able crying for 3 h within 48 h after a prior dose of any vac-
cine; and human immunodeficiency virus infection.
The study and all protocol revisions were approved by the
Ethics Committees of the Soroka University Medical Center,
the Maccabi Health Services Helsinki Committee, and the Na-
tional Ministry of Health Ethics Committee.
Procedures. The study was initiated in August 2005, and
enrollment lasted through March 2008. The study was initially
designed to examine the effect of various immunization sched-
ules on vaccine immunogenicity and pneumococcal nasopha-
ryngeal carriage.
In this open-label, randomized trial, 2 intervention groups
(randomized at a 2:1 ratio) were studied: a 3-dose primary
immunization series (at the ages of 2, 4, and 6 months) and a
2-dose primary immunization series (at the ages of 4 and 6
months) (Figure 1). Randomization was performed using ran-
dom number calculation, and the assigned randomization was
1572 • JID 2010:201 (15 May) • Dagan et al
Figure 1. Flow diagrams for study groups. NP, nasopharyngeal; OP, oropharyngeal. *The 3-dose group was randomized 1:1 to receive either a 7-
valent pneumococcal conjugate vaccine booster dose or no booster dose at 12 months of age. **In 4 children, serum for serologic tests was available
after the booster doses but not after the primary immunization series.
presented in a sealed opaque envelope that was opened only
after consent was obtained. The 3-dose primary immunization
group was further randomized (1:1) to receive or not receive
a booster PCV7 dose at 12 months of age. All children receiving
the 2-dose primary vaccination series were assigned to receive
a booster dose at 12 months.
The study vaccine was PCV7 (Wyeth Vaccines) containing
2 mg of serotypes 4, 9V, 14, 19F, and 23F polysaccharide, 4 mg
of serotype 6B polysaccharide, and 2 mg of serotype 18C oli-
gosaccharide, linked to the diphtheria toxoid protein CRM197
(lots A94431D, B08636C, 808672K, and C659732).
All infants received concomitant vaccines, including a com-
bined diphtheria, tetanus, acellular pertussis, Haemophilus in-
fluenzae type b, and inactivated poliovirus vaccine (Glaxo-
SmithKline Biologicals) at ages 2, 4, 6 and 12 months and a
measles, mumps, and rubella vaccine (GlaxoSmithKline Bio-
logicals) at age 12 months.
Nasopharyngeal and oropharyngeal swab samples were ob-
tained at the time of first dose (age, 2 months) for the 3-dose
primary group and at ages 2 and 4 months for the 2-dose
primary group. The nasopharyngeal cultures were kept in trans-
port swabs (MW173 Amies transport medium [Transwab,
Medical Wire and Equipment] for nasopharyngeal samples;
Culture Swab Transport System [Venturi Transystem, Copan
Innovation] oropharyngeal samples) at room temperature until
processed by the microbiology laboratory within 16 h. Results
of the oropharyngeal swab samples were used only if S. pneumo-
niae did not grow from the nasopharyngeal swab samples. Iden-
tification and serotyping of S. pneumoniae were performed as
described elsewhere [22].
A total of 2–4 mL of blood was drawn before vaccination
(age, 2 months), 1 month after the primary dose (age, 7
months), and 1 month after the booster dose (age, 13 months).
Blood samples were kept refrigerated and centrifuged in the
laboratory within 24 h.
Serologic assays. Serum serotype-specific pneumococcal an-
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Figure 2. Streptococcus pneumoniae nasopharyngeal carriers at or shortly before the first 7-valent (val) pneumococcal conjugate vaccine booster
(PCV7) dose in children receiving either 3 primary PCV7 doses (at ages 2, 4, and 6 months [m]) or 2 primary PCV7 doses (ages 4 and 6 months) who
were serologically evaluable 1 month after the primary PCV7 series (age 7 months); 7-val VT indicates the serotypes included in PCV7. In 14 children
of the 2 + 1 group (see Methods), from whom a VT serotype was isolated, a non-VT serotype was also isolated at a previous or subsequent visit.
ticapsular immunoglobulin (Ig) G concentrations were tested by
enzyme-linked immunosorbent assay at the Department of Ap-
plied Immunology and Endocrinology, Kinder und Jugendklinik
Universita¨tsklinikum Erlangen, after double absorption with C
polysaccharide and serotype 22F polysaccharide [23–25].
Statistical analysis. Data were analyzed with SPSS software
(version 14.0 for Windows). Contingency table analyses for
comparing rates were performed using x2 or Fisher’s exact test,
as appropriate. Continuous variables including geometric mean
concentration (GMC) comparisons were analyzed using t test
or analysis of variance procedures. Because carriage rates often
differ between Jewish and Bedouin infants, and because ma-
ternally derived pneumococcal anti-polysaccharide antibodies
are often more common in Bedouin infants, ethnicity was cor-
rected for using Mantel-Haenszel or linear regression analysis.
Differences were considered significant at P ! .05.
RESULTS
A total of 545 infants were randomized to receive either 3-dose
primary vaccination (3 + 1 group; np356) or 2-dose primary
vaccination (2 + 1 group; np189) (Figure 1). Of these, 302
(85%) of 356 subjects and 157 (83%) of 189 subjects in the
3 + 1 and 2 + 1 groups, respectively, had an initial nasopharyn-
geal culture and were evaluable for serologic response at the
postprimary vaccination visit (age 7 months). The 3 + 1 and
2 + 1 groups were comparable in proportions of male subjects
(45%–50% for all visits). The mean ages ( standard devia-
tions) at the first, second, third, and booster doses for the 3 -
+ 1 group were 2.10.2, 4.00.4, 5.80.6, and 12.50.7
months. The mean ages at the first, second, and booster doses
for the 2 + 1 group were 3.90.3, 5.70.4, and 12.40.5
months. At enrollment, 51% and 38% of the subjects were
Bedouin in the 3 + 1 and 2 + 1 groups, respectively.
At the enrollment visit (age, 2 months), 127 (42%) of 302
infants in the 3 + 1 group carried S. pneumoniae, of whom 54
(18%) carried a serotype included in PCV7 (VT serotype) and
73 (24%) carried a non-VT serotype (Figure 2). For the 2 + 1
group, because the first dose was given at 4 months of age,
carriage at both 2 and 4 months was investigated. Pneumo-
coccal carriage at 2 and/or 4 months was detected in 77 of the
157 infants (49%) (9 at age 2 months, 25 at 4 months, and 43
at both 2 and 4 months). Of the 157 infants, 42 (27%) and 48
(31%) carried VT and non-VT serotypes, respectively.
The most commonly carried VT serotypes at or shortly be-
fore the first PCV7 dose were 6B, 19F, and 23F (Figure 2); these
constituted the study serotypes, because carriage of the other
4 VT serotypes was not prevalent enough to be studied.
Carriage of serotypes 6B, 19F, and 23F at or shortly before
the first PCV7 dose resulted in both a decreased GMC of the
anticapsular IgG antibodies and a lower proportion of children
with concentrations of 0.35 mg/mL against the carried se-
rotype in both the 3 + 1 and 2 + 1 groups (Tables 1 and 2 and
Figures 3–5). This difference was significant in all comparisons,
except for serotype 23F in the 2 + 1 group, an arm with only
4 children. In contrast, when IgG GMCs were measured for
the serotypes not retrieved from the nasopharynx around the
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Table 1. Serotype-Specific Anticapsular Immunoglobulin (Ig) G Levels in Children Who Carried Streptococcus pneumoniae Se-
rotypes 6B, 19F, or 23F at or Shortly before the First Dose of 7-Valent Pneumococcal Conjugate Vaccine Booster (PCV7)
Serotype carriage groups
and anticapsular IgG antibodies
Subjects receiving PCV7 at ages 2, 4,
and 6 months (3 + 1 group)
Subjects receiving PCV7 at ages 4
and 6 months (2 + 1 group)
Positive before
vaccination
Negative before
vaccination P a
Positive before
vaccination (n
Negative before
vaccination P a
Serotype 6B carriers vs noncarriers
No. of subjects 16 286 21 136
IgG, GMC (95% CI), mg/mL
Anti-6B IgGb 0.35 (0.12–1.00) 2.29 (1.92–2.72) !.001 0.23 (0.11–0.46) 0.66 (0.53–0.82) !.001
Anti-19F IgG 2.78 (1.63–4.74) 1.90 (1.66–2.18) .175 3.31 (1.48–7.40) 1.99 (1.56–2.54) .054
Anti-23F IgG 1.78 (1.10–2.88) 1.11 (0.96–1.28) .124 0.78 (0.42–1.44) 0.61 (050–0.75) .479
Serotype 19F carriers vs noncarriers
No. of subjects 13 289 9 148
IgG, GMC (95% CI), mg/mL
Anti-6B IgG 1.42 (0.52–3.83) 2.11 (1.76–2.53) .429 1.11 (0.48–2.54) 0.55 (0.44–0.68) .154
Anti-19F IgGb 0.49 (0.13–1.87) 2.07 (1.82–2.34) !.001 0.17 (0.05–0.66) 2.48 (2.00–3.08) !.001
Anti-23F IgG 1.50 (0.68–3.29) 1.12 (0.98–1.30) .324 0.50 (0.30–0.83) 0.64 (0.53–0.79) .430
Serotype 23F carriers vs noncarriers
No. of subjects 10 292 4 153
IgG, GMC (95% CI), mg/mL
Anti-6B IgG 3.45 (1.49–7.99) 2.03 (1.69–2.44) .266 1.20 (0.15–9.78) 0.56 (0.45–0.69) .298
Anti-19F IgG 2.31 (0.90–5.91) 1.93 (1.89–2.21) .511 1.17 (0.12–11.33) 2.17 (1.71–2.75) .612
Anti-23F IgGb 0.44 (0.10–1.93) 1.19 (1.04–1.36) .014 0.45 (0.03–6.76) 0.64 (0.53–0.78) .517
NOTE. Antibody concentrations were measured at age 7 months (1 month after completion of the primary series). CI, confidence interval; GMC, geometric
mean concentration.
a P values adjusted for ethnicity (Jewish vs Bedouin infants).
b Antibodies against the carried serotype.
time of first PCV7 dose (namely, GMC for serotypes 19F and
23F for those carrying serotype 6B, serotypes 6B and 23F for
those carrying 19F, and serotypes 6B and 19F for those carry-
ing 23F), no significant differences in postprimary series IgG
GMCs were observed between carriers and noncarriers. Thus,
a clear hyporesponsiveness was observed for each of the 3
studied serotypes in subjects carrying these serotypes around
the time of the first PCV7 dose. This phenomenon was not
seen when these serotypes were not carried at this time.
We investigated whether this hyporesponsiveness persisted
after booster dose administration at age 12 months (Figures 3–
5). As can be clearly seen, although all groups showed a clear
booster response, the serotype-specific GMCs were lower in
children carrying the given serotypes around the administration
of the first PCV7 dose than in those not carrying the serotypes.
These differences reached statistical significance for serotype 6B
in both 3 + 1 and 2 + 1 groups and for serotype 19F in the 2
+ 1 group. In contrast to the carried serotypes, no significant
differences in postbooster IgG GMC between groups were ob-
served for serotypes not carried around the time of the first
dose.
We determined whether carriage or its effect was related to
serotype-specific IgG concentrations at the time of vaccination
(representing maternal antibody) (Figure 3–5). No significant
difference between carriers and noncarriers was found in serum
anticapsular IgG GMCs at the time of first dose administration
for any of the serotypes tested.
DISCUSSION
PCVs elicit a T cell–dependent response and thus are highly
immunogenic in infancy [4, 7]. However, we demonstrated in
the present study that pneumococcal nasopharyngeal carriage
shortly before the first infant dose of PCV7 resulted in hy-
poresponsiveness to the capsular polysaccharide of the carried
strain. This serotype-specific hyporesponsiveness was only par-
tially overcome after 2 or 3 PCV7 doses. Furthermore, although
an additional PCV7 dose administered at 12 months elicited a
booster dose response, the response was blunted in children
who had carried the specific serotype around the time of the
first PCV7 dose, at age 2 or 4 months. Preliminary results from
our study showed high correlation between the concentrations
measured by enzyme-linked immunosorbent assay (as shown
in the present article) and the more functional opsonophag-
ocytosis assay (data not shown).
What could be the reasons for this hyporesponsiveness to
PCV7 observed in pneumococcal carriers? Because the first
PCV7 dose was administered at age 2 months, when the cir-
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Table 2. Proportions of Subjects with Serotype-Specific Anticapsular Immunoglobulin (Ig) G Levels 0.35 mg/mL among Infants
Who Carried Streptococcus pneumoniae Serotypes 6B, 19F, or 23F at or Shortly before the First Dose of 7-Valent Pneumococcal
Conjugate Vaccine Booster (PCV7)
Group
Subjects receiving PCV7 at ages 2, 4,
and 6 months (3 + 1 group)
Subjects receiving PCV7 at ages 4
and 6 months (2 + 1 group)
Positive before
vaccination
Negative before
vaccination Pa
Positive before
vaccination
Negative before
vaccination P
Serotype 6B carriers vs noncarriers
No. of subjects 16 285 21 136
No. (%) with IgG 0.35 mg/mL
Anti-6B IgGb 6 (38) 255 (89) !.001 6 (29) 90 (66) .002
Anti-19F IgG 16 (100) 265 (93) .998 19 (90) 121 (89) .586
Anti-23F IgG 16 (100) 241 (85) .998 15 (71) 95 (70) .924
Serotype 19F carriers vs noncarriers
No. of subjects 13 288 9 148
No. (%) with IgG 0.35 mg/mL
Anti-6B IgG 12 (92) 249 (86) .520 7 (78) 89 (60) .303
Anti-19F IgGb 7 (54) 274 (95) !.001 4 (44) 136 (92) .002
Anti-23F IgG 11 (85) 246 (85) .856 7 (78) 103 (70) .643
Serotype 23F carriers vs noncarriers
No. of subjects 10 291 4 153
No. (%) with IgG 0.35 mg/mL
Anti-6B IgG 10 (100) 251 (86) .999 3 (75) 93 (61) .576
Anti-19F IgG 9 (90) 272 (93) .913 3 (75) 137 (90) .583
Anti-23F IgGb 6 (60) 251 (86) .053 2 (50) 108 (71) .360
NOTE. Antibody concentrations were measured at age 7 months (1 month after completion of the primary series). PCV7, 7-valent pneumococcal
conjugate vaccine booster.
a P values adjusted for ethnicity (Jewish vs Bedouin infants).
b Antibodies against the carried serotype.
culating anti-polysaccharide IgG is essentially maternally de-
rived, can these results reflect differences in maternally derived
antibody concentration? In principle, maternally derived an-
tibodies can be associated with both differences in colonization
rates and responses to PCV7. However, no differences in spe-
cific anti-polysaccharide IgG antibody concentrations between
carriers and noncarriers for any of the serotypes tested were
observed at 2 months of age. Thus, the role of maternal an-
tibodies could be ruled out.
Could pneumococcal carriage affect innate immunity, anti-
gen-presenting cells, or T cells required for B cell help, resulting
in reduced antibody response to PCVs? Such a general mech-
anism can be excluded, because the hyporesponsiveness was
serotype specific: immune responses were blunted only to the
carried serotype, responses to other serotypes remaining un-
affected. The same rationale rules out genetic factors, because
the subjects responded appropriately to all tested serotypes
other than the carried serotype.
Another potentially plausible explanation is that carriage re-
sulted in the absorption and circulation of high loads of pneu-
mococcal polysaccharide, which could compete with the re-
spective polysaccharide antigen included in PCV7. Although
such a competition could affect responses to the first vaccine
dose, serotype-specific carriage-associated polysaccharide load
is unlikely to persist throughout the primary and booster dose
series (ie, 10 months) [26–28].
Having excluded the previous potential mechanisms for the
observed serotype-specific hyporesponsiveness, we are left with
the most likely plausible explanation, namely, the B cell exhaus-
tion or fatigue mechanism. B cell hyporesponsiveness caused by
the injection of polysaccharide antigens has been largely de-
scribed. Several randomized clinical trials in adults 50 years
old using 23-valent PPSV (PPSV23) showed that a second dose
of PPSV23 administered within !5 years after the first dose was
associated with clear hyporesponsiveness [9, 10, 29, 30]. Hy-
poresponsiveness observed after PPSV23 administration in the
elderly was partially overcome by PCV7 administered as the sec-
ond dose. However, a PCV7 dose administered 1 year after
PPSV23 injection still elicited generally lower anticapsular IgG
concentrations than these obtained in subjects not previously
primed with PPSV23 [9, 31].
B cell hyporesponsiveness after the administration of PPSV
was also observed in infants. This was first described in group
C meningococcal polysaccharide vaccines [32, 33]. This hypo-
responsiveness was partially overcome by meningococcal con-
jugate vaccine [7, 34]. Only a few studies have investigated mul-
Figure 3. Anticapsular immunoglobulin G geometric mean concentrations (GMCs) and 95% confidence intervals at ages 2 months (m) (prevaccination),
7 months (1 month after primary 7-valent pneumococcal conjugate vaccine booster [PCV7] series), and 13 months (1 month after booster dose) in
subjects who carried serotype 6B shortly before or at the first PCV7 dose versus noncarriers. Children belonged to either the 3 + 1 or the 2 + 1 group
(see Methods). In the 3 + 1 group, only half of the children were assigned to receive a booster dose. P values were adjusted for ethnicity (Jewish vs
Bedouin infants). *In the 3 + 1 group, only one-half of the children were assigned to receive a booster dose.
Figure 4. Anticapsular immunoglobulin G geometric mean concentrations (GMCs) and 95% confidence intervals at ages 2 months (m) (prevaccination),
7 months (1 month after primary 7-valent pneumococcal conjugate vaccine booster [PCV7] series), and 13 months (1 month after booster dose) in
subjects who carried serotype 19F shortly before or at the first PCV7 dose versus noncarriers. Children belonged to either the 3 + 1 or the 2 + 1 group
(see Methods). In the 3 + 1 group, only half of the children were assigned to receive a booster dose. P values were adjusted for ethnicity (Jewish vs
Bedouin infants). *In the 3 + 1 group, only one-half of the children were assigned to receive a booster dose.
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Figure 5. Anticapsular immunoglobulin G geometric mean concentrations (GMCs) and 95% confidence intervals at ages 2 months (prevaccination),
7 months (1 month after primary 7-valent pneumococcal conjugate vaccine booster [PCV7] series) and 13 months (1 month after booster dose) in
subjects who carried serotype 23F shortly before or at the first PCV7 dose versus noncarriers. Children belonged to either the 3 + 1 or the 2 + 1 group
(see Methods). In the 3 + 1 group, only half of the children were assigned to receive a booster dose. P values were adjusted for ethnicity (Jewish vs
Bedouin infants). *In the 3 + 1 group, only one-half of the children were assigned to receive a booster dose.
tiple doses of PPSV in infants, and most showed that antibody
concentrations after the second PPSV dose were lower than after
the first [4]. However, no systematic studies were conducted to
assess whether the use of PCVs can overcome PPSV-induced
hyporesponsiveness in healthy infants or toddlers. In 1 study
with a limited number of subjects, we showed that when a second
PPSV23 dose was administered to healthy toddlers 1 year after
the first dose, the response was lower than that after the first
dose for several serotypes. This reduction was not seen if PCV
was given instead of PPSV23 [11].
Anecdotal reports have suggested that serotype-specific hy-
poresponsiveness to polysaccharide antigens can be induced by
pneumococcal invasive infections. In 2 case reports, 2 children
who experienced IPD were unable to respond to the infecting
serotype but could respond to other serotypes when given a
PPSV (2 weeks and 27 months after the events for serotypes
14 and 18C, respectively) [35, 36]. In a recent report, 8 children
aged 3.1–16.3 months who had experienced IPD failed to de-
velop a response to the infecting serotype (despite receiving3
doses of PCV7). None of these children had underlying risk
factors for IPD, and their responses to the other PCV7 serotypes
were adequate [5].
The most likely explanation for our observation is that B
cell fatigue or unresponsiveness may also be elicited in healthy
infants by nasopharyngeal carriage. Carriage during early in-
fancy may result in absorption and circulation of high poly-
saccharide antigen loads and may persist for several months
[26–28]. These circulating polysaccharides are expected to bind
to serotype-specific infant B cells, especially in the marginal
zone of the spleen and nodes. In the absence of carrier-induced
T cell help, in the poorly developed marginal zones, immature
infant B cells do not effectively differentiate into antibody-
producing plasma cells in response to polysaccharides [37, 38].
Our observation that children carrying a given vaccine serotype
shortly before the first PCV7 immunization fail to respond to
this specific serotype indicates that their B cells may not be
activated even by an otherwise immunogenic conjugate vaccine.
This implies that B cell fatigue or unresponsiveness may be
driven by nasopharyngeal carriage in healthy young infants,
whose pool of marginal zone B cells is limited [37, 38]. In our
study, this phenomenon persisted at least through the first year
of life. Whether and when it can be fully overcome is an open
question.
The blunting of vaccine responses in carrier children may
not be restricted to young infants. In 1 study, the administra-
tion of 1 dose of PCV7 to 1-year-old toddlers resulted in sig-
nificantly lower anti-9V antibody concentration 9–11 days after
immunization in 8 children carrying S. pneumoniae serotype
9V at the time of immunization than in 152 children not car-
rying this serotype [39]. However, no significant differences
were demonstrated for the other serotypes.
Although we could study only the 3 serotypes carried at a
sufficient frequency at 2–4 months of age, which is a limitation
of our study, the importance of carriage-induced B cell ex-
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haustion is indeed expected to decline with the age-associated
maturation of the marginal zone B cell pool. Whether various
serotypes differ in their vulnerability to carriage-induced B cell
exhaustion, depending on their binding characteristics and the
size of the serotype-specific B cell pool, is a plausible hypothe-
sis that remains to be studied.
The present study clearly demonstrates, for the first time,
that serotype-specific hyporesponsiveness can occur in infants
even as a result of pneumococcal colonization, a much more
common situation than IPD, and that PCV7 can only partially
overcome this phenomenon. Nasopharyngeal pneumococcal
colonization in infants is common, especially in crowded pop-
ulations such as those in the developing world, where most
severe and fatal pneumococcal diseases occur. In developing
countries or among indigenous populations, pneumococcal
carriage exceeds 50%–75% by the age of 2 months, about the
time the first PCV7 dose is usually recommended [40]. In our
study 140% of infants carried S. pneumoniae at the time of the
first PCV7 dose, and 18%–27% carried a serotype included in
PCV7. Thus, the potential of reduced response to PCV7 in
populations with high pneumococcal carriage rates during early
infancy may be substantial. The clinical significance of this phe-
nomenon is still unclear. However, the fact that hyporesponsive-
ness persisted after 3 doses and often, though to a lesser extent,
after a booster dose, suggests that these infants may be at higher
risk than their noncarrier peers for disease caused by the carried
serotypes.
Can carriage-induced hyporesponsiveness limit PCV7 vac-
cine efficacy? The exact relationship between reduced anti-
body response and disease is not entirely clear. A reduced pro-
portion of children achieving antibody concentrations above a
given threshold after the primary immunization series, as ob-
served here for serotypes 6B, 19F, and 23F, is indeed expected
to result in reduced PCV7 efficacy against IPD [41, 42]. Pro-
tection against the more common mucosal pneumococcal dis-
eases, such as acute otitis media and pneumonia, or against car-
riage, is more likely to relate to higher IgG concentration, but
the exact threshold is not known [43]. Accordingly, the finding
that carriage at the time of the first PCV7 dose results in IgG
GMCs that are several-fold lower for each of the carried serotypes
suggests a lower vaccine efficacy against mucosal end points
among carriers [44, 45].
This first report of the negative influence of previous ex-
posure or carriage on PCV vaccine responses calls for a careful
examination and selection of optimal immunization schedules.
In areas of intense and early pneumococcal colonization, car-
riage may affect immune response in a large number of infants,
posing a public health threat. In such areas, providing a booster
dose may be important. In addition, immunization during or
shortly after the 4-week neonatal period may result in improved
protective efficacy, by reducing the chance of becoming a carrier
shortly before immunization. However, this possibility needs
still to be studied.
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